The role of plasma atherogenic index in patients with NAFLD

Year 2023, Volume: 5 Issue: 3, 185 - 190, 29.07.2023

Ali Kırık , Hacer Şen

https://doi.org/10.46310/tjim.1256322

Abstract

Background Plasma atherogenic index (PAI) is a novel index investigated in recent years related to cardiovascular disease and atherosclerosis. The role of PAI is not clear in non-alcoholic fatty liver disease (NAFLD). This study aimed to examine the role of PAI in patients with NAFLD and its relationship with metabolic components.
Material and Methods This study was designed as a retrospective study, and the patients' files admitted to the Internal Medicine unit were retrospectively scanned. Within the scope of the study, demographic and laboratory data of the groups with and without NAFLD were compared.
Results A total of 234 patients were evaluated, 159 of which were NAFLD (age: 39.52 ± 10.38 years) and 75 controls (age: 38.07 ± 12.11 years) (p = 0.374). PAI level was statistically significantly higher in the NAFLD group compared to the control group (p = 0.006). In the whole group correlation analysis, PAI level and body mass index (p < 0.001, r = 0.363), waist circumference (p < 0.001, r = 0.366), systolic blood pressure (p < 0.001, r = 0.333), diastolic blood pressure (p = 0.001, r = 0.210), ALT (p < 0.001, r = 0.312), AST (p = 0.005, r = 0.182), fasting plasma glucose (p = 0.017, r = 0.157) and insulin resistance (p < 0.001, r = 0.302) values were positively correlated.
Conclusions PAI level was higher in patients with NAFLD; this index was associated with other metabolic components, especially insulin resistance. This indicates that the PAI level may be associated with clinical progression in the pathogenesis and course of the disease.

Keywords

Non-alcoholic fatty liver disease, plasma atherogenic index, insulin resistance

Supporting Institution

None.

Project Number

None.

Thanks

None.

References

• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431.
• European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004.
• Mato JM, Alonso C, Noureddin M, Lu SC. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World J Gastroenterol. 2019 Jun 28;25(24):3009-20. doi: 10.3748/wjg.v25.i24.3009.
• Souza MR, Diniz Mde F, Medeiros-Filho JE, Araújo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012 Jan-Mar;49(1):89-96. doi: 10.1590/s0004-28032012000100015.
• Chang Y, Li Y, Guo X, Dai D, Sun Y. The association of ideal cardiovascular health and atherogenic index of plasma in rural population: A cross-sectional study from Northeast China. Int J Environ Res Public Health. 2016 Oct 19;13(10):1027. doi: 10.3390/ijerph13101027.
• Zhang X, Zhang X, Li X, Feng J, Chen X. Association of metabolic syndrome with atherogenic index of plasma in an urban Chinese population: A 15-year prospective study. Nutr Metab Cardiovasc Dis. 2019 Nov;29(11):1214-9. doi: 10.1016/j.numecd.2019.07.006.
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9. doi: 10.1007/BF00280883.
• Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G, Dadgarmoghaddam M. Atherogenic index of Pplasma (AIP): A marker of cardiovascular disease. Med J Islam Repub Iran. 2015 Jul 25;29:240.
• Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007 Dec;102(12):2708-15. doi: 10.1111/j.1572-0241.2007.01526.x.
• Xie F, Zhou H, Wang Y. Atherogenic index of plasma is a novel and strong predictor associated with fatty liver: a cross-sectional study in the Chinese Han population. Lipids Health Dis. 2019 Sep 12;18(1):170. doi: 10.1186/s12944-019-1112-6.
• Dong BY, Mao YQ, Li ZY, Yu FJ. The value of the atherogenic index of plasma in non-obese people with non-alcoholic fatty liver disease: a secondary analysis based on a cross-sectional study. Lipids Health Dis. 2020 Jun 23;19(1):148. doi: 10.1186/s12944-020-01319-2.
• Fadaei R, Meshkani R, Poustchi H, Fallah S, Moradi N, Panahi G, Merat S, Golmohammadi T. Association of carotid intima media thickness with atherogenic index of plasma, apo B/apo A-I ratio and paraoxonase activity in patients with non-alcoholic fatty liver disease. Arch Physiol Biochem. 2019 Feb;125(1):19-24. doi: 10.1080/13813455.2018.1429475.
• Kessoku T, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Kawaguchi T, Nakajima A; Japan Study Group of NAFLD. Insulin resistance correlated with the severity of liver histology in Japanese NAFLD patients: a multicenter retrospective study. J Clin Gastroenterol. 2015 Feb;49(2):169-70. doi: 10.1097/MCG.0000000000000186.
• Fujii H, Imajo K, Yoneda M, Nakahara T, Hyogo H, Takahashi H, Hara T, Tanaka S, Sumida Y, Eguchi Y, Chayama K, Nakajima A, Nishimoto N, Kawada N; Japan Study Group of Nonalcoholic Fatty Liver Disease. HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2019 Aug;34(8):1390-5. doi: 10.1111/jgh.14595.